This Series on “Biomarkers in Acute Coronary Syndromes” is edited by Dr. Eric Boersma from Erasmus University Medical Center Rotterdam, the Netherlands.
Eric Boersma, MSc, PhD, FESC
Department of Cardiology, Erasmus University Medical Center Rotterdam, the Netherlands
Dr. Boersma received his Master of Applied Mathematics from the Technical University of Delft in 1990. He completed his PhD thesis on clinical decision-making in acute myocardial infarction in 1998 and completed his Masters of Epidemiology in 2001 at the Erasmus University Rotterdam.
With a background in mathematics and clinical epidemiology, Dr. Boersma was appointed as Professor of Clinical Epidemiology at the Erasmus MC in 2008, and Scientific Director of the Cardiovascular Research School of the Erasmus MC in 2012. Dr. Boersma obtained grants for 25 projects during his research carreer, and he currently supervises 6 granted research projects.
Dr. Boersma has over 25 years’ research experience in the fields of cardiovascular diseases and biostatistics. Dr. Boersma has been member or Chair of over 10 Erasmus MC committees and member of several national and international committees, including the Dutch Medicines Agency Board, and clinical guideline committees of the European Society of Cardiology. Dr. Boersma is also member of the international editorial board of the European Heart Journal (since 2007), the American Heart Journal (since 2009), and the American Journal of Medicine (since 2009).
Dr Boersma has co-authored over 1000 papers in international peer-reviewed scientific journals and his H-index is 110 from the citation report of ISI Web of Knowledge. He has mentored over 40 PhD students and he has been reviewer for a number of internationally esteemed journals.
- Introductory Preface for Biomarkers in Acute Coronary Syndromes
- Biomarker-based cardiovascular risk stratification in the general population
- Biomarker-based risk stratification in cardiovascular compromised populations
- Biomarkers for early diagnosis and classification of acute coronary syndromes
- Short-term prognosis after acute coronary syndrome admission: what do biomarkers tell us?
- The role of biomarkers for long-term risk stratification after acute coronary syndromes: insights from clinical trials and registries
- Optimizing management of acute coronary syndromes by using biomarkers
- The prognostic value of repeated biomarker measurements in acute coronary syndromes
- Sex-specific biomarker thresholds for acute coronary syndrome management
The series “Biomarkers in Acute Coronary Syndromes” was commissioned by the editorial office, Journal of Laboratory and Precision Medicine without any sponsorship or funding. Eric Boersma is serving as the unpaid Guest Editor for the series.